Romosozumab

罗莫索珠单抗

Report date: 2026/04/04 20:00:24
First In Class

Base Information

Drug NameRomosozumab
Drug Alias NameRomosozumab-AQQG罗莫组单抗洛莫索珠单抗Romosozumabum罗莫索单抗 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSclerostin inhibitors
TargetsSclerostin
Therapy Area/IndicationsFractures, BoneOsteoporosis, PostmenopausalOsteoporosis +[5] 
Global Approved IndicationsOsteoporosis, PostmenopausalOsteoporosis
Approved Indications in ChinaOsteoporosis
Original Approved Country/TerritoryJapan
Original Approved Date2019/01/08
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUcb Pharma SaAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesUcb Biopharma SrlUcb Trading (Shanghai) Co Ltd
Active IndicationsOsteoporosis, PostmenopausalOsteoporosisOsteogenesis Imperfecta
Inactive IndicationsFractures, BoneBone Diseases, Metabolic

Other Information

ATC CodeM05BX06
Related LinksWikipediaDrugBankKEGG